George Jesso, Devi Padmini, Kamath Deepak Y, Anthony Naveen, Kunnoor Nitin S, Sanil Sandra S
Department of Pharmacology, St John's Medical College, Bangalore 560034, Karnataka, India.
J Cardiovasc Dis Res. 2013 Dec;4(4):214-21. doi: 10.1016/j.jcdr.2013.12.001. Epub 2014 Feb 6.
A wide variation exists in the patterns of pharmacotherapy among patients admitted with cardiovascular diseases. Very few studies have evaluated the potential determinants of drug utilization. Our objective was to evaluate the clinical characteristics and patterns of cardiovascular drug utilization among patients in coronary care unit (CCU) and assess the determinants of cardiovascular drug use among patients with coronary artery disease (CAD).
In this retrospective cohort study, the medical records of CCU patients were reviewed independently by two trained physicians over one year. Patients were analyzed as two groups - those with CAD and without CAD. Multivariate logistic regression was done to identify the determinants of cardiovascular drug utilization in the CAD group.
Of 574 patients, 65% were males, 57% were <60 years. The five commonly prescribed drug classes were platelet inhibitors (88.7%), statins (76.3%), ACE-inhibitors/Angiotensin receptor blockers (72%), beta-blockers (58%) and heparin (57%). Poly-pharmacy (>5 drugs) was noticed in 71% of patients. A majority of patients had diagnosis of CAD (72.6%). CAD patients received significantly higher median number of drugs and had longer duration of CCU stay (p < 0.0001). Renal dysfunction for ACE-inhibitors [0.18 (0.09-0.36)], ST-elevation myocardial infarction for calcium channel blockers [0.29 (0.09-0.93)] and brady-arrhythmias for beta-blockers [0.3 (0.2-0.7)] were identified as determinants of decreased drug use in CAD group.
Predominance of male gender, age <60 and poly-pharmacy was observed in CCU. Antithrombotics, statins, ACE-inhibitors/Angiotensin receptor blockers and beta-blockers were the most frequently prescribed drugs. Clinical co-morbidities (renal dysfunction, arrhythmias) decreased the utilization of ACE-inhibitors, beta-blockers among CAD patients.
因心血管疾病入院的患者在药物治疗模式上存在很大差异。很少有研究评估药物使用的潜在决定因素。我们的目的是评估冠心病监护病房(CCU)患者的临床特征和心血管药物使用模式,并评估冠状动脉疾病(CAD)患者心血管药物使用的决定因素。
在这项回顾性队列研究中,两名经过培训的医生对CCU患者的病历进行了为期一年的独立审查。患者被分为两组——患有CAD的患者和未患有CAD的患者。进行多因素逻辑回归分析以确定CAD组心血管药物使用的决定因素。
在574名患者中,65%为男性,57%年龄小于60岁。五种最常用的药物类别是血小板抑制剂(88.7%)、他汀类药物(76.3%)、ACE抑制剂/血管紧张素受体阻滞剂(72%)、β受体阻滞剂(58%)和肝素(57%)。71%的患者存在联合用药(>5种药物)。大多数患者被诊断为CAD(72.6%)。CAD患者接受的药物中位数显著更高,CCU住院时间更长(p<0.0001)。ACE抑制剂的肾功能不全[0.18(0.09 - 0.36)]、钙通道阻滞剂的ST段抬高型心肌梗死[0.29(0.09 - 0.93)]以及β受体阻滞剂的缓慢性心律失常[0.3(0.2 - 0.7)]被确定为CAD组药物使用减少的决定因素。
在CCU中观察到男性占主导、年龄小于60岁以及联合用药的情况。抗血栓药、他汀类药物、ACE抑制剂/血管紧张素受体阻滞剂和β受体阻滞剂是最常用的药物。临床合并症(肾功能不全、心律失常)降低了CAD患者中ACE抑制剂和β受体阻滞剂的使用。